TAS2R8
ENSG00000121314
Target class
GPCR
Chromosome
12
- Chemical probe available
- No
- Target name
- TAS2R8
- Gene name
- Taste 2 receptor member 8
- Gene symbol
- TAS2R8
- Protein name
- Taste receptor type 2 member 8 (T2R8) (Taste receptor family B member 5) (TRB5)
- T2R8
- TRB5
- Gene biotype
- Protein coding
- Gene family
- Taste 2 receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 0
- Highest tissue expression
- 0.13
- Tissue specificity (Gini)
- 0.907
- Tissue specificity (tau)
- 0.951
- KEGG gene identifiers
- hsa:50836
- Protein interaction confidence
- 0.905
- Protein interaction partners
- 1
- R-HSA-418594
- R-HSA-420499
- R-HSA-9717207
- End position
- 10807286
- Start position
- 10806051
- Chromosome
- 12
- Strand
- Reverse
- Membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.950653
- Expression inequality (Gini)
- 0.907407
Expression in transcripts per million
- Brain - Cerebellum
- 0.13
- Brain - Cerebellar Hemisphere
- 0.11
- Pituitary
- 0.07
- Brain - Frontal Cortex (BA9)
- 0.05
- Brain - Cortex
- 0.04
Expression in transcripts per million
- Brain - Cerebellum0.13
- Brain - Cerebellar Hemisphere0.11
- Pituitary0.07
- Brain - Frontal Cortex (BA9)0.05
- Brain - Cortex0.04
- Brain - Hypothalamus0.04
- Adrenal Gland0.03
- Ovary0
- Colon - Transverse0
- Cells - Cultured fibroblasts0
- Brain - Nucleus accumbens (basal ganglia)0
- Breast - Mammary Tissue0
- Spleen0
- Whole Blood0
- Skin - Not Sun Exposed (Suprapubic)0
- Brain - Spinal cord (cervical c-1)0
- Esophagus - Mucosa0
- Esophagus - Muscularis0
- Brain - Hippocampus0
- Adipose - Subcutaneous0
- Colon - Sigmoid0
- Uterus0
- Stomach0
- Small Intestine - Terminal Ileum0
- Brain - Anterior cingulate cortex (BA24)0
And 29 more, listed on the interactive page.
Biological processes
- GO:0001580
- GO:0005886
- GO:0016020
- GO:0005515
- GO:0008527
- GO:0033038
Related records
Trials (762)
- "The Once A Day Protease Inhibitor Regimens"
- 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
- A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
- A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
- A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
- A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients
- A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
- A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
- A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort
- A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.
- A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
- A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
- A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
- A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers
- A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
- A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects
- A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
- A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
- A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
- A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir
Drugs (4)
- Andrographolide
- Chloramphenicol
- Parthenolide
- Ritonavir